3Singh Saluja S, Sharma R, Pal S, et al. Differentiation be- tween benign and malignant hilar obstructions using labo- ratory and radiolgial investigations: a prospective study [J]. HPB(Oxford) ,2007,9(5):373-382.
4Sasakia T, Kawano K, Inomata M, et al. Value of serum carbohydrate antigen 19- 9 for predicting ertrahepatic me- tastasisin patients will liver metastas is from colorectal carcinoma [J]. Hepatogastroenterolgy, 2005, 52 ( 10 ) 1814-1820.
5Dnogahy A, Ramage JK, Fasant JM, et al. Strum tumor mark for the dignoses of cholnagiocacrinoma in primary sclerosing cholangtis [J]. Gastroen-trerology, 2005, 106 (8) :765-769.
6Sheen-Chen SM, Sun CK, Liu YW, et al. Extremely ele- vated CA19-9 in acute cholangitis[J]. Dig Dis Sci, 2007, 52(11) :3140-3142.
7Michiko Watanabe,Miyoshi Chigusa,Hiroki Takahashi,Junta Nakamura,Hisako Tanaka,Tsuneya Ohno. High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo[J] 2000,In Vitro Cellular & Developmental Biology - Animal(2):104～109
8De Waele E, Op de Beeck B, De Waele B, et al. Magnetic reso-nance cholangiopancreatography in the preoperative assessmentof patients with biliarypancreatitis [j].Pancreatology,2007,7(4):347-351.
9Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA,CA19-9, and CA242 in the diagnosis and prognosis of pancreat-ic cancer[j]. Eur J Surg Oncol,2005,31 (2): 164—169.
10Szajda SD,Waszkiewicz N,Chojnowska S, et al. Carbohydratemarkers of pancreatic cancer [j ] .Biochem Soc Trans, 2011,39(1):340-343.
